Search Results - "Laimito, K.I. Rojas"

50P Transcriptomic profiles of CD32b in breast cancer predict outcome and are associated with immune activation by Rojas Laimito, K.I., Vieito Villar, M., Galvao de Aguiar, V., Saavedra Santa Gadea, O., Lostes Bardaji, M.J., Oberoi, A., Alonso, G., Brana, I., Tabernero, J., Garralda, E.

Get full text

45P In silico transcriptomic mapping of Notch biological pathway in luminal breast cancer by Laimito, K.I. Rojas, Martin, M.R., Rojo, F., Gámez-Pozo, A., De Castro, F.J., Vegas, E. Filipovich, Viro, J. Ceballos, Martínez, J.E. Ales

Get full text

672P Phase I/II trial of RVU120 (SEL120), CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors by Dziadziuszko, R., Lugowska, I., Garralda, E., Rojas Laimito, K.I., Rzymski, T., Dudziak, R., Littlewood, P., Nogai, H., Boni, V., Fuentes Antras, J., Alonso, G., Saavedra Santa Gadea, O., Kuklík, R.

Get full text

1075TiP A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors by Dumbrava, E.E., Calvo, E., Garralda, E., Ryu, M.H., Oh, D-Y., Bai, L-Y., Chung, W., Rojas Laimito, K.I., Yildirim, O., Masciari, S., Kang, K., Buday, B., Rharbaoui, F., Abbadessa, G., Moreno Garcia, V.

Get full text

21P Transcriptomic mapping of integrins and immune activation in high-grade serous ovarian cancer by Rojas Laimito, K.I., Ocana Fernandez, A., Villena, M.V., Gonzalez Larriba, J.L., Puente Vásquez, J., Rubio, M.J., García-Martínez, H., Garcia-Donas, J., Manso Sánchez, L.

Get full text

538P Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials by Pretelli, G., Laimito, K.I. Rojas, Alonso, G., Bardaji, M.J. Lostes, Calvo, A. Hernando, Galvao, V., Oberoi, A., Morillo, B. Ortega, Santa Gadea, O. Saavedra, Moya, J. Ginard, Manich, C. Saura, Fernandez, M.E. Elez, Ortiz, C., Couselo, E. Muñoz, Braña, I., Perez, A. Callejo, Galceran, J. Carles, Felip, E., Garralda, E., Villar, M. Vieito

Get full text

702P Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy by Rojas Laimito, K.I., Vieito Villar, M., Moya Hernández, M.Á., Pretelli, G., Lostes Bardaji, M.J., Saavedra Santa Gadea, O., Hernando Calvo, A., Galvao, V., Oberoi, A., Alonso, G., Braña, I., Ginard Moya, J., Baraibar Argota, I., Saura Manich, C., Muñoz Couselo, E., Macarulla, T., Garcia Duran, C., Carles Galceran, J., Tabernero, J., Garralda, E.

Get full text

702P Genomic alterations in epigenetic modifiers and response to epigenetic-targeted agents (ETAs) in patients (pts) with recurrent/metastatic (R/M) salivary gland tumours (SGTs) by Rezqallah Aron, M.A., Hernando-Calvo, A., Galvao de Aguiar, V., Saavedra Santa Gadea, O., Assaf Pastrana, J.D., Lostes Bardaji, M.J., Rojas Laimito, K.I., Aguilar Izquierdo, S., Berché, R., Tian, T., Bescós, C., Lorente, J., Giralt, J., Temprana-Salvador, J., Alberola, M., Dienstmann, R., Felip, E., Garralda, E., Vieito Villar, M., Brana, I.

Get full text

77P Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy by Vieito Villar, M., Rojas Laimito, K.I., López, D., Berché, R., Saavedra Santa Gadea, O., Alonso Casal, G., Galvao de Aguiar, V., Lostes Bardaji, M.J., Braña, I., Tabernero, J., Garralda Cabanas, E.

Get full text

99P Molecular correlates and treatment outcomes of patients with brain metastasis included in early phase trials: A single-center retrospective analysis by Pretelli, G., Laimito, K.I. Rojas, Casal, G. Alonso, Bardaji, M.J. Lostes, Calvo, A. Hernando, Galvao, V., Oberoi, A., Morillo, B. Ortega, Mirallas, O., Santa Gadea, O. Saavedra, Manich, C. Saura, Fernandez, M.E. Elez, Ortiz, C., Couselo, E. Muñoz, Braña, I., Galceran, J.C., Felip, E., Garralda, E., Villar, M. Vieito

Get full text

93P Evolving landscape of targeted therapies (TT) in early phase clinical trials (EPCT): The RESISTANCE project (360R) by Rossi, A., Braña, I., Villar, M. Vieito, Casal, G. Alonso, Santa Gadea, O. Saavedra, Mirallas, O., Bardaji, M.J. Lostes, Galvao, V., Laimito, K.I. Rojas, Oberoi, A., Pretelli, G., Morillo, B. Ortega, Sanz, M., Izquierdo, S. Aguilar, Raskina, K., Dienstmann, R., Vivancos, A., Tabernero, J., Garralda, E., Calvo, A. Hernando

Get full text

29O Clinical characterization of long-term survivors in phase I clinical trials by Mirallas, O., Rossi, A., Fernández, E.M., Garcia-Galea, E., Cano, K.S. Vega, Moya, J. Ginard, Calvo, A. Hernando, Pretelli, G., Bardaji, M.J. Lostes, Oberoi, A., Galvao, V., Laimito, K.I. Rojas, Morillo, B. Ortega, Casal, G. Alonso, Izquierdo, S. Aguilar, Braña, I., Dienstmann, R., Villar, M. Vieito, Garralda, E.

Get full text

27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target by Yap, T.A., Cervantes, A., Falchook, G., Patel, M., Juric, D., Waqar, S.N., Schenk, E., Shapiro, G., Boni, V., Perez, C.A., Burtness, B., Najjar, Y., Racca, F.E., Rojas Laimito, K.I., Kuplast-Barr, K., McEachern, K., Samant, M., Bozón, V., Parasuraman, S., Johnson, M.L.

Get full text

51P Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit by Rojas Laimito, K.I., Vieito Villar, M., Fullana Grimalt, B., Berché, R., Hierro Carbo, C., Saavedra Santa Gadea, O., Braña, I., Alonso Casal, G., Galvao de Aguiar, V., Lostes Bardaji, M.J., Oliveira, M., Verdaguer, H., Morales Barrera, R., Garcia Duran, C., Zamora, E., Carles Galceran, J., Macarulla, T., Tabernero, J., Garralda Cabanas, E.

Get full text